| |
| |
|
| Insider
Information: |
Springhorn Jeremy P. |
| Relationship: |
Director |
| City: |
Amsterdam |
| State: |
P7 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
54,573 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$271,347 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
54,573 |
|
|
| Total
Value |
$271,347 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -96.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Syros Pharmaceuticals, Inc. |
SYRS |
Chief Business Officer |
2019-11-12 |
35,000 |
2017-12-15 |
0 |
Premium* |
|
|
uniQure B.V. |
QURE |
Director |
2023-02-27 |
19,573 |
2018-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
15 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| QURE |
uniQure B.V. |
Director |
– • – |
2023-02-27 |
4 |
S |
$20.41 |
$7,837 |
D/D |
(384) |
19,573 |
0 |
% |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,080 |
19,957 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
10,877 |
0 |
% |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
11,479 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2021-03-02 |
4 |
S |
$37.50 |
$18,938 |
D/D |
(505) |
9,945 |
0 |
% |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
10,450 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
8,068 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2020-01-28 |
4 |
S |
$60.94 |
$50,190 |
D/D |
(807) |
6,005 |
0 |
% |
|
| SYRS |
Syros Pharmaceuticals, In... |
Chief Business Officer |
• – – |
2019-11-12 |
4 |
AB |
$4.97 |
$50,268 |
D/D |
10,121 |
35,000 |
0 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Chief Business Officer |
• – – |
2019-11-11 |
4 |
AB |
$4.99 |
$49,328 |
D/D |
9,879 |
24,879 |
0 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Chief Business Officer |
• – – |
2019-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
87,000 |
102,000 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2019-01-28 |
4 |
S |
$31.32 |
$37,897 |
D/D |
(1,210) |
6,812 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
8,022 |
0 |
- |
|
| QURE |
uniQure B.V. |
Director |
– • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
4,792 |
0 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Chief Business Officer |
• – – |
2017-12-15 |
4 |
B |
$9.08 |
$136,260 |
D/D |
15,000 |
15,000 |
2.74 |
- |
|
15 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
